ORKA 001
Alternative Names: ORKA-001; ORKA-021; PR-035Latest Information Update: 22 Sep 2025
At a glance
- Originator Paragon Therapeutics
- Developer Oruka Therapeutics; Paragon Therapeutics
- Class Antibodies; Antipsoriatics; Monoclonal antibodies
- Mechanism of Action Interleukin-23 subunit p19 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Plaque psoriasis
Most Recent Events
- 17 Sep 2025 Pharmacokinetics, pharmacodynamics and adverse events data from a phase I trial in plaque psoriasis (In Volunteers) released by Oruka Therapeutics
- 17 Sep 2025 Oruka Therapeutics plans a phase IIb EVERLAST-B trial for Plaque psoriasis in first half of 2026
- 31 Jul 2025 The Health Canada approves an IND application for a phase IIa EVERLAST-A trial of ORKA 001 in Psoriasis